Validation of 7th TNM staging system for lung cancer, based on surgical outcomes

Yukihiro Yoshida, Tomonori Murayama, Yasunori Sato, Yoshio Suzuki, Haruhisa Saito, Nobutaka Tanaka

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Validation of the clinical classification for lung cancer of the 7th edition of the TNM staging system among surgical cases has not been reported previously. Methods: Data of 489 males and 246 females, with a mean age of 67.6 years, who underwent surgical resection for nonsmall- cell lung cancer were analyzed retrospectively. Results: The 5-year survival rate of these patients was 72.2% for clinical stage IA (n=365), 58.4% for IB (n=158), 51.2% for IIA (n=77), 49.1% for IIB (n=42), 36.8% for IIIA (n=86), 80% for IIIB (n=5) and 50% for IV (n=2). The 5-year survival rate of patients was 100% for pathological stage 0 (n=2), 86.1% for IA (n=216), 73.8% for IB (n=173), 46.1% for IIA (n=97), 47.2% for IIB (n=69), 33.3% for IIIA (n=155), 33.3% for IIIB (n=3) and 30.9% for IV (n=20). Prognostic factors included female sex and 70 years of age or younger, as well as adenocarcinoma histology. Conclusions: Deterioration in patient survival was indicated with the exception of stages IIIB and IV, each of which included only a small number of patients. Our study validated the current TNM staging system in surgical cases with regard to both clinical and pathological classifications.

Original languageEnglish
Pages (from-to)693-699
Number of pages7
JournalAsian Cardiovascular and Thoracic Annals
Volume21
Issue number6
DOIs
Publication statusPublished - 2013 Dec 2
Externally publishedYes

Fingerprint

Neoplasm Staging
Lung Neoplasms
Survival Rate
Non-Small Cell Lung Carcinoma
Histology
Adenocarcinoma
Survival

Keywords

  • Carcinoma
  • lung neoplasms
  • neoplasm staging
  • non-small-cell lung
  • survival rate
  • thoracic surgery

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Validation of 7th TNM staging system for lung cancer, based on surgical outcomes. / Yoshida, Yukihiro; Murayama, Tomonori; Sato, Yasunori; Suzuki, Yoshio; Saito, Haruhisa; Tanaka, Nobutaka.

In: Asian Cardiovascular and Thoracic Annals, Vol. 21, No. 6, 02.12.2013, p. 693-699.

Research output: Contribution to journalArticle

Yoshida, Y, Murayama, T, Sato, Y, Suzuki, Y, Saito, H & Tanaka, N 2013, 'Validation of 7th TNM staging system for lung cancer, based on surgical outcomes', Asian Cardiovascular and Thoracic Annals, vol. 21, no. 6, pp. 693-699. https://doi.org/10.1177/0218492312470670
Yoshida, Yukihiro ; Murayama, Tomonori ; Sato, Yasunori ; Suzuki, Yoshio ; Saito, Haruhisa ; Tanaka, Nobutaka. / Validation of 7th TNM staging system for lung cancer, based on surgical outcomes. In: Asian Cardiovascular and Thoracic Annals. 2013 ; Vol. 21, No. 6. pp. 693-699.
@article{c06a93bf50ea4ff3893858c25efaccd1,
title = "Validation of 7th TNM staging system for lung cancer, based on surgical outcomes",
abstract = "Background: Validation of the clinical classification for lung cancer of the 7th edition of the TNM staging system among surgical cases has not been reported previously. Methods: Data of 489 males and 246 females, with a mean age of 67.6 years, who underwent surgical resection for nonsmall- cell lung cancer were analyzed retrospectively. Results: The 5-year survival rate of these patients was 72.2{\%} for clinical stage IA (n=365), 58.4{\%} for IB (n=158), 51.2{\%} for IIA (n=77), 49.1{\%} for IIB (n=42), 36.8{\%} for IIIA (n=86), 80{\%} for IIIB (n=5) and 50{\%} for IV (n=2). The 5-year survival rate of patients was 100{\%} for pathological stage 0 (n=2), 86.1{\%} for IA (n=216), 73.8{\%} for IB (n=173), 46.1{\%} for IIA (n=97), 47.2{\%} for IIB (n=69), 33.3{\%} for IIIA (n=155), 33.3{\%} for IIIB (n=3) and 30.9{\%} for IV (n=20). Prognostic factors included female sex and 70 years of age or younger, as well as adenocarcinoma histology. Conclusions: Deterioration in patient survival was indicated with the exception of stages IIIB and IV, each of which included only a small number of patients. Our study validated the current TNM staging system in surgical cases with regard to both clinical and pathological classifications.",
keywords = "Carcinoma, lung neoplasms, neoplasm staging, non-small-cell lung, survival rate, thoracic surgery",
author = "Yukihiro Yoshida and Tomonori Murayama and Yasunori Sato and Yoshio Suzuki and Haruhisa Saito and Nobutaka Tanaka",
year = "2013",
month = "12",
day = "2",
doi = "10.1177/0218492312470670",
language = "English",
volume = "21",
pages = "693--699",
journal = "Asian Cardiovascular and Thoracic Annals",
issn = "0218-4923",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Validation of 7th TNM staging system for lung cancer, based on surgical outcomes

AU - Yoshida, Yukihiro

AU - Murayama, Tomonori

AU - Sato, Yasunori

AU - Suzuki, Yoshio

AU - Saito, Haruhisa

AU - Tanaka, Nobutaka

PY - 2013/12/2

Y1 - 2013/12/2

N2 - Background: Validation of the clinical classification for lung cancer of the 7th edition of the TNM staging system among surgical cases has not been reported previously. Methods: Data of 489 males and 246 females, with a mean age of 67.6 years, who underwent surgical resection for nonsmall- cell lung cancer were analyzed retrospectively. Results: The 5-year survival rate of these patients was 72.2% for clinical stage IA (n=365), 58.4% for IB (n=158), 51.2% for IIA (n=77), 49.1% for IIB (n=42), 36.8% for IIIA (n=86), 80% for IIIB (n=5) and 50% for IV (n=2). The 5-year survival rate of patients was 100% for pathological stage 0 (n=2), 86.1% for IA (n=216), 73.8% for IB (n=173), 46.1% for IIA (n=97), 47.2% for IIB (n=69), 33.3% for IIIA (n=155), 33.3% for IIIB (n=3) and 30.9% for IV (n=20). Prognostic factors included female sex and 70 years of age or younger, as well as adenocarcinoma histology. Conclusions: Deterioration in patient survival was indicated with the exception of stages IIIB and IV, each of which included only a small number of patients. Our study validated the current TNM staging system in surgical cases with regard to both clinical and pathological classifications.

AB - Background: Validation of the clinical classification for lung cancer of the 7th edition of the TNM staging system among surgical cases has not been reported previously. Methods: Data of 489 males and 246 females, with a mean age of 67.6 years, who underwent surgical resection for nonsmall- cell lung cancer were analyzed retrospectively. Results: The 5-year survival rate of these patients was 72.2% for clinical stage IA (n=365), 58.4% for IB (n=158), 51.2% for IIA (n=77), 49.1% for IIB (n=42), 36.8% for IIIA (n=86), 80% for IIIB (n=5) and 50% for IV (n=2). The 5-year survival rate of patients was 100% for pathological stage 0 (n=2), 86.1% for IA (n=216), 73.8% for IB (n=173), 46.1% for IIA (n=97), 47.2% for IIB (n=69), 33.3% for IIIA (n=155), 33.3% for IIIB (n=3) and 30.9% for IV (n=20). Prognostic factors included female sex and 70 years of age or younger, as well as adenocarcinoma histology. Conclusions: Deterioration in patient survival was indicated with the exception of stages IIIB and IV, each of which included only a small number of patients. Our study validated the current TNM staging system in surgical cases with regard to both clinical and pathological classifications.

KW - Carcinoma

KW - lung neoplasms

KW - neoplasm staging

KW - non-small-cell lung

KW - survival rate

KW - thoracic surgery

UR - http://www.scopus.com/inward/record.url?scp=84888337099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888337099&partnerID=8YFLogxK

U2 - 10.1177/0218492312470670

DO - 10.1177/0218492312470670

M3 - Article

VL - 21

SP - 693

EP - 699

JO - Asian Cardiovascular and Thoracic Annals

JF - Asian Cardiovascular and Thoracic Annals

SN - 0218-4923

IS - 6

ER -